Cyclophosphamide-induced acute respiratory distress syndrome.
Cyclophosphamide is widely used in neoplastic and inflammatory diseases. Although several adverse events have been described with its use, acute and subacute interstitial pneumonitis leading to pulmonary fibrosis is rare and potentially fatal. This case report describes a 64-year-old man who, after the fifth chemotherapy cycle, developed a severe ARDS leading to pulmonary fibrosis in just 30 days.
Brieva
Jorge
J
Intensive Care Unit, Mater Misericordiae Hospital, Newcastle, New South Wales, Australia. jorge.brieva@mater.health.nsw.gov.au
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide / Q000009:adverse effects*; D004317:Doxorubicin; D006801:Humans; D008168:Lung / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone; D011658:Pulmonary Fibrosis / Q000209:etiology; D012128:Respiratory Distress Syndrome / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D014750:Vincristine
D018906:Antineoplastic Agents, Alkylating; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone